Cross-reactivity occurs when IgE recognises similar molecular structures across different allergen sources. This can produce multiple positive results, but those results do not automatically mean the patient has multiple clinically relevant allergies.

Common cross-reactive patterns

  • PR-10 proteins linking birch-related pollen sensitisation with some plant foods.
  • Profilins and polcalcins contributing to broad pollen positivity.
  • Tropomyosins linking mite, cockroach, shellfish, and parasite-related patterns.
  • Serum albumins and lipocalins contributing to cross-reactivity among furry animals.
  • CCD-related IgE producing broad in vitro positivity with variable clinical relevance.

Molecular allergology can help clinicians identify whether a pattern is dominated by a broadly cross-reactive protein family or whether it suggests genuine sensitisation to a specific allergen source. This distinction can change how the result is explained, how risk is discussed, and whether further specialist assessment is needed.

Common interpretation trap

A broad panel of positive tests can look alarming when read as a list. Read molecularly, some results may reflect a shared protein family rather than separate primary allergies. The educational task is to move from lists to patterns.

Clinical context still leads

History remains essential. Timing of symptoms, reproducibility, dose, route of exposure, geography, pollen season, diet, cofactors, and previous tolerance all influence how molecular results should be understood.

How molecular testing helps

Component testing can identify whether multiple positives share a protein family. If they do, the interpretation may shift from "many separate allergies" to "one sensitisation pattern with cross-reactive expression." That distinction matters for communication, avoidance advice, referral, and deciding what remains uncertain.

How it can mislead

A molecular panel can also create false confidence if read without context. A named component may sound precise, but precision is not the same as clinical relevance. The result still needs a patient story.

Teaching point

Molecular allergology does not simply create more data. Used well, it reduces ambiguity by showing which positives may belong to the same biological story.